Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride is a potassium salt that dissociates in solution to provide potassium ions, essential for maintaining intracellular tonicity, nerve impulse transmission, cardiac, skeletal, and smooth muscle contraction, and acid-base balance. Dextrose is a monosaccharide that provides caloric support and may prevent ketosis. Sodium chloride provides sodium and chloride ions for electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; rate determined by patient's fluid and electrolyte needs; typical maintenance: 0.22% KCl in D5% and 0.2% NaCl at 100-125 mL/hour; potassium replacement: up to 10 mEq/hour via peripheral line, not to exceed 200 mEq/day.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: 2–3 hours (redistribution phase). Dextrose: 15–20 minutes. Clinical context: half-life reflects rapid redistribution; in renal impairment, potassium elimination is prolonged.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium: 90% renal, 10% fecal. Dextrose: metabolized to CO2 and H2O; no significant renal/fecal excretion. Sodium chloride: excreted renally.
Category C
Category A/B
Electrolyte
Electrolyte